Clinical trials
Phase 2 Mucositis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 7 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 6 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Terminated | 8 |
| Withdrawn | 6 |
| Unknown status | 6 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tarix Pharmaceuticals | 3 |
| Tosk, Inc. | 3 |
| EpicentRx, Inc. | 2 |
| Radboud University Medical Center | 2 |
| Roswell Park Cancer Institute | 2 |
| Universidade Federal do Rio Grande do Norte | 2 |
| AHS Cancer Control Alberta | 1 |
| AM-Pharma | 1 |
| Aaron Cumpston, PharmD, BCOP | 1 |
| Access Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mucositis | 56 |
| Stomatitis | 16 |
| Head and Neck Neoplasms | 15 |
| Neoplasms | 7 |
| Squamous Cell Carcinoma of Head and Neck | 7 |
| Xerostomia | 6 |
| Hematologic Neoplasms | 3 |
| Mouth Neoplasms | 3 |
| Radiation Injuries | 3 |
| Breast Neoplasms | 2 |
Trials
Showing 26 to 50 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.